Indus Gene Expressions Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
as on 19-06-2024
- Paid Up Capital ₹ 78.36 Cr
as on 19-06-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 32.63 Cr
as on 19-06-2024
- Satisfied Charges ₹ 30.40 Cr
as on 19-06-2024
- Revenue 1429.59%
(FY 2022)
- Profit -48.25%
(FY 2022)
- Ebitda -1122.12%
(FY 2022)
- Net Worth 25.80%
(FY 2022)
- Total Assets 17.94%
(FY 2022)
About Indus Gene Expressions
The Corporate was formerly known as Indus Gene Expressions Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 78.36 Cr.
The company currently has active open charges totaling ₹32.63 Cr. The company has closed loans amounting to ₹30.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Indus Gene Expressions Limited India is Usharani C as CFO. Himadeep Nallavadla, Muktha Krishna, Avula Reddy, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24231AP2007PLC113311
- Company No.
113311
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Ananthapur, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Indus Gene Expressions?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Usharani C  | CFO | 03-Apr-2019 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Himadeep Nallavadla  | Director | 27-Apr-2013 | Current |
| Muktha Krishna | Additional Director | 27-Jan-2023 | Current |
| Avula Reddy | Additional Director | 28-Oct-2019 | Current |
| Meka Reddy | Additional Director | 06-May-2022 | Current |
| Channa C | Director | 06-Nov-2008 | Current |
| Rupana Nallari | Director | 07-Oct-2013 | Current |
Financial Performance and Corporate Structure Insights of Indus Gene Expressions.
Indus Gene Expressions Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1429.59% increase. The company also saw a substantial fall in profitability, with a 48.25% decrease in profit. The company's net worth Soared by an impressive increase of 25.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indus Gene Expressions?
In 2022, Indus Gene Expressions had a promoter holding of 44.22% and a public holding of 55.78%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Halo Energie Chitradurga Private LimitedActive 9 years 3 months
Himadeep Nallavadla is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 04 Sep 2020 | ₹3.63 Cr | Open |
Syndicate Bank Creation Date: 21 Dec 2019 | ₹29.00 Cr | Open |
Andhra Bank Creation Date: 13 Oct 2014 | ₹30.40 Cr | Satisfied |
How Many Employees Work at Indus Gene Expressions?
Unlock and access historical data on people associated with Indus Gene Expressions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indus Gene Expressions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indus Gene Expressions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
